Click here to go to the previous page
Vasculopathy in Sickle Cell Disease
Program Code:
9306-S
Date:
Monday, October 8, 2012
Time:
10:30 AM to 12:00 PM
EST
SPEAKER
(S):
Robert Hebbel, MD
Mark Gladwin, MD, Chair, Department of Medicine, University of Pittsburgh
David Nathan, MD, President Emeritus, Dana-Farber Cancer Institute
Description
Hb S polymerization in red cells of people with sickle cell disease results in vascular damage. How this vascular damage occurs is multifactorial, involving viscosity, nitric oxide, oxidative stress, ischemia-reperfusion injury, and activation of leukocytes, platelets and coagulation. Pulmonary hypertension is a manifestation of vasculopathic end-stage organ damage with clinical and prognostic importance. The current status of adenosine A2A receptor agonist therapy will be described, as will plans for an antibody trial against invariant natural killer T cells.
CE Category | CE Value |
---|
California Clinical Laboratory Personnel |
1.5 |
California Nurse |
1.8 |
Florida Laboratory Personnel |
1.8 |
General Attendee |
1.5 |
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.